Siamab Therapeutics Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$202M
Siamab Therapeutics General Information
Description
Developer of a technology platform designed to develop therapies targeting cancers. The company's technology platform develops products based on new biological discoveries of non-human sialic acids, their dietary role and inflammatory consequences and their impact on cancer, cardiovascular and other inflammatory mediated diseases, enabling scientists in research of oncology, and antibody engineering to support anti-TACA antibody discovery and development programs.
Contact Information
Website
www.siamab.comCorporate Office
- 90 Bridge Street
- Suite 100
- Newton, MA 02458
- United States
Corporate Office
- 90 Bridge Street
- Suite 100
- Newton, MA 02458
- United States
Siamab Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 19-Aug-2019 | $202M | Completed | Out of Business | ||
| 9. Angel (individual) | 01-Apr-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 07-Nov-2018 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 29-Mar-2016 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B2) | 23-Sep-2014 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B2) | 10-Jul-2014 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B1) | 10-Oct-2012 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 16-Aug-2011 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 19-Mar-2010 | $700K | $700K | Completed | Startup | |
| 1. Grant | Completed | Startup |
Siamab Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A6 | ||||||||
| Series A5 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 3,000,000 | $0.001000 | $0.02 | $0.35 | $0.35 | 1x | $0.35 | 4.25% |
| Series A1 | 2,500,000 | $0.001000 | $0.02 | $0.35 | $0.35 | 1x | $0.35 | 3.54% |
Siamab Therapeutics Comparisons
Industry
Financing
Details
Siamab Therapeutics Competitors (101)
One of Siamab Therapeutics’s 101 competitors is etherna, a Formerly VC-backed company based in Niel, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Pure MHC | Formerly VC-backed | Austin, TX | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Siamab Therapeutics Patents
Siamab Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018160909-A1 | Glycan-interacting compounds and methods of use | Inactive | 03-Mar-2017 | ||
| WO-2018094144-A1 | Compositions and methods for treating cancer | Inactive | 17-Nov-2016 | ||
| WO-2018094143-A1 | Glycan-interacting compounds and methods of use | Inactive | 17-Nov-2016 | ||
| WO-2017132486-A1 | Compositions and methods for targeting cancer stem cells | Inactive | 27-Jan-2016 | ||
| JP-2019500020-A | Glycan interacting compounds and methods of use | Active | 12-Nov-2015 | A61K47/6851 |
Siamab Therapeutics Signals
Siamab Therapeutics Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bantam Group | Angel Group | Minority | ||
| Beacon Angels | Angel Group | Minority | ||
| Angel (individual) | Minority | |||
| Boston Harbor Angels | Angel Group | Minority | ||
| Desert Angels | Angel Group | Minority |
Siamab Therapeutics FAQs
-
When was Siamab Therapeutics founded?
Siamab Therapeutics was founded in 2006.
-
Where is Siamab Therapeutics headquartered?
Siamab Therapeutics is headquartered in Newton, MA.
-
What is the size of Siamab Therapeutics?
Siamab Therapeutics has 9 total employees.
-
What industry is Siamab Therapeutics in?
Siamab Therapeutics’s primary industry is Drug Discovery.
-
Is Siamab Therapeutics a private or public company?
Siamab Therapeutics is a Private company.
-
What is the current valuation of Siamab Therapeutics?
The current valuation of Siamab Therapeutics is .
-
What is Siamab Therapeutics’s current revenue?
The current revenue for Siamab Therapeutics is .
-
How much funding has Siamab Therapeutics raised over time?
Siamab Therapeutics has raised $21.5M.
-
Who are Siamab Therapeutics’s investors?
Bantam Group, Beacon Angels, , Boston Harbor Angels, and Desert Angels are 5 of 14 investors who have invested in Siamab Therapeutics.
-
Who are Siamab Therapeutics’s competitors?
etherna, CytomX Therapeutics, TME Pharma, Pure MHC, and Sorrento Therapeutics are some of the 101 competitors of Siamab Therapeutics.
-
When was Siamab Therapeutics acquired?
Siamab Therapeutics was acquired on 19-Aug-2019.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process